- Home
- SOC vs URGN Comparison
SOC vs URGN Comparison
Compare SOC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOC | URGN |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | 200 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SOC | URGN |
|---|---|---|
| Price | $10.15 | $33.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $17.33 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 4.4M | 605.5K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | N/A | $129.09 |
| Revenue Next Year | $73.55 | $70.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.72 | $12.73 |
| 52 Week High | $32.18 | $33.79 |
Technical Indicators
Market Signals| Indicator | SOC | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.74 | 73.21 |
| Support Level | $6.75 | $18.58 |
| Resistance Level | $15.27 | N/A |
| Average True Range (ATR) | 1.19 | 1.67 |
| MACD | -0.31 | 0.45 |
| Stochastic Oscillator | 12.57 | 97.18 |
Price Performance
Historical ComparisonAbout SOC Sable Offshore Corp.
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.